Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

65th Annual Scientific Session of the American College of Cardiology

2-4 April 2016, Chicago, USA

ACC 2016: Late Breaker underscores the value of genetic testing in ascertaining coronary risk in FH

ACC 2016: Late Breaker underscores the value of genetic testing in ascertaining coronary risk in FH

A key paper for the familial hypercholesterolaemia (FH, inherited high cholesterol) community was presented at the clinical Latebreaker session. According to PCSK9 Forum Board member, Professor Gerald Watts, University of Western Australia, Perth, Australia, the paper by Khera and co-workers not only confirms the higher…

read more »
American College of Cardiology updates guidance for non-statin therapies for LDL-C lowering

American College of Cardiology updates guidance for non-statin therapies for LDL-C lowering

In a prelude to this year’s Annual Congress, the American College of Cardiology has released a new consensus document to address gaps from the 2013 ACC/American Heart Association (AHA) guidelines (1) regarding the use of non-statin therapies for lowering LDL cholesterol. This important document provides…

read more »
Latebreaker Clinical Trial GAUSS-3: Evolocumab in patients with statin intolerance

Latebreaker Clinical Trial GAUSS-3: Evolocumab in patients with statin intolerance

While confirming the superior LDL cholesterol lowering efficacy of evolocumab over ezetimibe, GAUSS-3 also highlights the difficulties of diagnosing statin intolerance, according to PCSK9 Forum Co-Editor Professor Henry Ginsberg. In contrast to the other two trials with evolocumab in statin intolerant patients, GAUSS-3 included an…

read more »
ACC 2016 Program

ACC 2016 Program

April 2, 2016 8:00 – 9:15 AM 404 – Joint American College of Cardiology/ Journal of the American Medical Association Late-Breaking Clinical Trials 404-10 – Comparison of PCSK9 Inhibitor Evolocumab Versus Ezetimibe in Statin-intolerant Patients: The Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin…

read more »